miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs
Authors
Keywords
-
Journal
LABORATORY INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-14
DOI
10.1038/s41374-018-0164-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib
- (2018) Jupeng Yuan et al. Clinical Lung Cancer
- Genetic variants in microRNAs and their binding sites within gene 3′UTRs associate with susceptibility to age-related macular degeneration
- (2017) Mohsen Ghanbari et al. HUMAN MUTATION
- A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population
- (2017) Kaipeng Xie et al. INTERNATIONAL JOURNAL OF CANCER
- miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2
- (2017) Norahayu Othman et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The long noncoding RNAPCAT-1links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma
- (2017) Yanli Ren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway
- (2017) Zhen Liang et al. Molecular Cancer
- Identification of miR-124a as a novel diagnostic and prognostic biomarker in non-small cell lung cancer for chemotherapy
- (2017) Pei Luo et al. Molecular Medicine Reports
- The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type
- (2017) Shuangshuang Wu et al. TUMOR BIOLOGY
- Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk
- (2016) Xinyu Yang et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
- (2016) Francesco Sclafani et al. CARCINOGENESIS
- Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population
- (2016) Zhihua Yin et al. LUNG CANCER
- Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
- (2015) F. Qiu et al. CLINICAL CANCER RESEARCH
- Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma
- (2015) KEIKO MIZUNO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients
- (2014) Barbara Pardini et al. CARCINOGENESIS
- A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
- (2014) M. Saito et al. CLINICAL CANCER RESEARCH
- A Genetic Variant in the Seed Region of miR-4513 Shows Pleiotropic Effects on Lipid and Glucose Homeostasis, Blood Pressure, and Coronary Artery Disease
- (2014) Mohsen Ghanbari et al. HUMAN MUTATION
- MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET
- (2014) Ying Zhang et al. PLoS One
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer Patients
- (2013) X. Pu et al. CANCER RESEARCH
- A Sequence Polymorphism in miR-608 Predicts Recurrence after Radiotherapy for Nasopharyngeal Carcinoma
- (2013) J. Zheng et al. CANCER RESEARCH
- Cancer heterogeneity—a multifaceted view
- (2013) Felipe De Sousa E Melo et al. EMBO REPORTS
- Bcl-xL Silencing Induces Alterations in hsa-miR-608 Expression and Subsequent Cell Death in A549 and SK-LU1 Human Lung Adenocarcinoma Cells
- (2013) Norahayu Othman et al. PLoS One
- microRNAs in cancer management
- (2012) Yi W Kong et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration
- (2011) Shilpi Arora et al. INTERNATIONAL JOURNAL OF CANCER
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation
- (2009) William C.S. Cho et al. EUROPEAN JOURNAL OF CANCER
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Let Me Count the Ways: Mechanisms of Gene Regulation by miRNAs and siRNAs
- (2008) Ligang Wu et al. MOLECULAR CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now